Molecular genetics of kidney cancer.

[1]  O. Hino,et al.  Tsc tumour suppressor proteins antagonize amino-acid–TOR signalling , 2002, Nature Cell Biology.

[2]  Tian Xu,et al.  Akt regulates growth by directly phosphorylating Tsc2 , 2002, Nature Cell Biology.

[3]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[4]  D. Siegel,et al.  Molecular advances in genetic skin diseases , 2002, Current opinion in pediatrics.

[5]  J. Blenis,et al.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. , 2002, Molecular cell.

[6]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[7]  M. Ligtenberg,et al.  Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3)(q35;q21). , 2002, Cancer genetics and cytogenetics.

[8]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[9]  P. Rustin.  Mitochondria, from cell death to proliferation , 2002, Nature Genetics.

[10]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[11]  B. Zbar,et al.  Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). , 2002, Human molecular genetics.

[12]  J. Moss,et al.  Giles F. Filley Lecture. Genetics and gene expression in lymphangioleiomyomatosis. , 2002, Chest.

[13]  H. Neumann,et al.  How many pathways to pheochromocytoma? , 2002, Seminars in nephrology.

[14]  B. Alman,et al.  A mutant PTH/PTHrP type I receptor in enchondromatosis , 2002, Nature Genetics.

[15]  E. Messing,et al.  Ubiquitination of a Novel Deubiquitinating Enzyme Requires Direct Binding to von Hippel-Lindau Tumor Suppressor Protein* , 2002, The Journal of Biological Chemistry.

[16]  J. Eble,et al.  Renal Disease in Adults With TSC2/PKD1 Contiguous Gene Syndrome , 2002, The American journal of surgical pathology.

[17]  E. Leteurtre,et al.  Renal oncocytoma with a novel chromosomal rearrangement, der(13)t(13;16)(p11;p11), associated with a renal cell carcinoma. , 2002, Journal of clinical pathology.

[18]  A. Jauch,et al.  TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/TSC2 frequency ratios , 2002, European Journal of Pediatrics.

[19]  K. Huebner,et al.  Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation , 2001, Journal of Human Genetics.

[20]  N. Minato,et al.  The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C* , 2001, The Journal of Biological Chemistry.

[21]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[22]  K. Huebner,et al.  The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation , 2001, Journal of Human Genetics.

[23]  W. Linehan,et al.  Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. , 2001, American journal of human genetics.

[24]  A. Stemmer-Rachamimov,et al.  Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. , 2001, American journal of human genetics.

[25]  B. Teh,et al.  Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2 , 2001, Oncogene.

[26]  Tetsuo Noda,et al.  A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. Eng,et al.  Genetic Disorders of Endocrine Neoplasia , 2001 .

[28]  B. Dickson,et al.  The Drosophila Tuberous Sclerosis Complex Gene Homologs Restrict Cell Growth and Cell Proliferation , 2001, Cell.

[29]  R. Houlston,et al.  Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. , 2001, American journal of human genetics.

[30]  M. Ligtenberg,et al.  Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15) , 2001, Genes, chromosomes & cancer.

[31]  D. Evans,et al.  Germline SDHD mutation in familial phaeochromocytoma , 2001, The Lancet.

[32]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[33]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[34]  D. Kwiatkowski,et al.  Molecular genetic aspects of the phakomatoses: tuberous sclerosis complex and neurofibromatosis 1 , 2001, Current opinion in neurology.

[35]  A. Bale,et al.  The hedgehog pathway and basal cell carcinomas. , 2001, Human molecular genetics.

[36]  L. Aaltonen,et al.  Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Burk,et al.  VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling , 2001, Molecular and Cellular Biology.

[38]  G. Rubin,et al.  gigas , a Drosophila Homolog of Tuberous Sclerosis Gene Product-2, Regulates the Cell Cycle , 1999, Cell.

[39]  D. Kwiatkowski,et al.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. , 2001, American journal of human genetics.

[40]  R. Burk,et al.  The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis , 2000, Oncogene.

[41]  Ulrich Müller,et al.  Mutations in SDHC cause autosomal dominant paraganglioma, type 3 , 2000, Nature Genetics.

[42]  B. Zbar.  Inherited epithelial tumors of the kidney: old and new diseases. , 2000, Seminars in cancer biology.

[43]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[44]  L. Schmidt,et al.  Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src , 2000, Oncogene.

[45]  B. Adryan,et al.  Tracheal development and the von Hippel–Lindau tumor suppressor homolog in Drosophila , 2000, Oncogene.

[46]  T. Shuin,et al.  Role of the von Hippel-Lindau tumor suppressor protein during neuronal differentiation. , 2000, Cancer research.

[47]  E. Henske,et al.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  A. Arnold,et al.  Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[49]  L. Hurst,et al.  Comparative sequence analysis of the VHL tumor suppressor gene. , 2000, Genomics.

[50]  R. Ve,et al.  Contemporary approach to the classification of renal epithelial tumors. , 2000 .

[51]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[52]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[53]  Janine Lewis,et al.  Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis , 1999, Human mutation.

[54]  B. Zbar,et al.  Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. , 1999, Archives of dermatology.

[55]  H. Onda,et al.  Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. , 1999, The Journal of clinical investigation.

[56]  R. Klausner,et al.  The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.

[57]  G. Semenza.  Perspectives on Oxygen Sensing , 1999, Cell.

[58]  W. Linehan,et al.  Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. , 1999, The New England journal of medicine.

[59]  H. Northrup,et al.  Tuberous Sclerosis Consensus Conference: Recommendations for Diagnostic Evaluation , 1999, Journal of child neurology.

[60]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[61]  V. Sukhatme,et al.  Transforming Growth Factor β1 Is a Target for the von Hippel-Lindau Tumor Suppressor and a Critical Growth Factor for Clear Cell Renal Carcinoma , 1999 .

[62]  S. Richard,et al.  Third International Meeting on von Hippel-Lindau disease. , 1999, Cancer research.

[63]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[64]  H. Northrup,et al.  Germ-line mosaicism in tuberous sclerosis: how common? , 1999, American journal of human genetics.

[65]  R. Lefkowitz,et al.  Regulation of tyrosine kinase cascades by G-protein-coupled receptors. , 1999, Current opinion in cell biology.

[66]  T. Noda,et al.  Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. , 1999, Cancer research.

[67]  D. Kwiatkowski,et al.  Mosaicism in tuberous sclerosis as a potential cause of the failure of molecular diagnosis. , 1999, The New England journal of medicine.

[68]  R. Klausner,et al.  Transcription-Dependent Nuclear-Cytoplasmic Trafficking Is Required for the Function of the von Hippel-Lindau Tumor Suppressor Protein , 1999, Molecular and Cellular Biology.

[69]  M. Gorospe,et al.  Protective Function of von Hippel-Lindau Protein against Impaired Protein Processing in Renal Carcinoma Cells , 1999, Molecular and Cellular Biology.

[70]  G. Semenza,et al.  Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. , 1999, Annual review of cell and developmental biology.

[71]  K. Artzt,et al.  Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[72]  H. Northrup,et al.  Tuberous Sclerosis Complex Consensus Conference: Revised Clinical Diagnostic Criteria , 1998, Journal of child neurology.

[73]  B. Scheithauer,et al.  Malignant tumors of the kidney, brain, and soft tissues in children and young adults with the tuberous sclerosis complex , 1998, Cancer.

[74]  W. Kaelin,et al.  von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. , 1998, Cancer research.

[75]  G. Semenza.  Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[76]  W. Kaelin,et al.  pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[77]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[78]  F. Li,et al.  The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[79]  P. Choyke,et al.  Familial renal oncocytoma: clinicopathological study of 5 families. , 1998, The Journal of urology.

[80]  R. Burk,et al.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Y. Pekarsky,et al.  Absence or reduction of Fhit expression in most clear cell renal carcinomas. , 1998, Cancer research.

[82]  G. Argenziano,et al.  Hereditary multiple fibrofolliculomas, trichodiscomas and acrochordons: syndrome of Birt-Hogg-Dubè. , 1998, Journal of the European Academy of Dermatology and Venereology : JEADV.

[83]  M. Delgado,et al.  Renal lesion growth in children with tuberous sclerosis complex. , 1998, The Journal of urology.

[84]  Campello,et al.  Haemangioblastoma of the central nervous system in von Hippel–Lindau disease , 1998, Journal of internal medicine.

[85]  Lips,et al.  The eye in von Hippel–Lindau disease. Long‐term follow‐up of screening and treatment: recommendations , 1998, Journal of internal medicine.

[86]  E. van den Berg,et al.  An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. , 1998, American journal of human genetics.

[87]  D. Louis,et al.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.

[88]  R. Snell,et al.  Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. , 1998, Human molecular genetics.

[89]  R. Klausner,et al.  The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  V. Sukhatme,et al.  Transforming Growth Factor α Is a Target for the Von Hippel-Lindau Tumor Suppressor , 1998 .

[91]  W. Linehan,et al.  Improved detection of germline mutations in the von Hippel‐Lindau disease tumor suppressor gene , 1998, Human mutation.

[92]  M. Lerman,et al.  Inherited carcinomas of the kidney. , 1998, Advances in cancer research.

[93]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[94]  A. Vortmeyer,et al.  Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. , 1997, The American journal of pathology.

[95]  S. Scherer,et al.  Gene structure of the human MET proto-oncogene , 1997, Oncogene.

[96]  J M Ward,et al.  Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[97]  S Povey,et al.  Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. , 1997, Science.

[98]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[99]  S. Richard,et al.  Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. , 1997, American journal of human genetics.

[100]  C. Larsson,et al.  Familial non-VHL non-papillary clear-cell renal cancer , 1997, The Lancet.

[101]  B. Zbar,et al.  Renal cysts, renal cancer and von Hippel-Lindau disease. , 1997, Kidney international.

[102]  W. Linehan,et al.  Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. , 1996, The American journal of pathology.

[103]  T. Sepp,et al.  Loss of heterozygosity in tuberous sclerosis hamartomas. , 1996, Journal of medical genetics.

[104]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[105]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[106]  K. Plate,et al.  Pathology, genetics and cell biology of hemangioblastomas. , 1996, Histology and histopathology.

[107]  J. Declue,et al.  Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[108]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[109]  A. Webster,et al.  Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. , 1996, Journal of medical genetics.

[110]  K. Méhes.  Familial association of supernumerary nipple with renal cancer. , 1996, Cancer genetics and cytogenetics.

[111]  R. Klausner,et al.  Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene. , 1996, Cancer treatment and research.

[112]  A. Webster,et al.  Clinical features and molecular genetics of Von Hippel-Lindau disease. , 1995, Ophthalmic genetics.

[113]  L. Schmidt,et al.  Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. , 1995, The cancer journal from Scientific American.

[114]  B. Scheithauer,et al.  Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band l6p13 occurs in sporadic as well as TSC‐associated renal angiomyolipomas , 1995, Genes, chromosomes & cancer.

[115]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[116]  J. Declue,et al.  Identification of Tuberin, the Tuberous Sclerosis-2 Product. TUBERIN POSSESSES SPECIFIC Rap1GAP ACTIVITY (*) , 1995, The Journal of Biological Chemistry.

[117]  R. Klausner,et al.  Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[118]  P. Choyke,et al.  Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma , 1995 .

[119]  P. Choyke,et al.  von Hippel-Lindau disease: genetic, clinical, and imaging features. , 1995, Radiology.

[120]  I. Zimmer-Galler,et al.  Long-term observation of retinal lesions in tuberous sclerosis. , 1995, American journal of ophthalmology.

[121]  P. Choyke,et al.  Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. , 1995, The Journal of urology.

[122]  W. Linehan,et al.  Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.

[123]  C. O'Brien,et al.  Supratentorial haemangioblastoma not associated with Von Hippel Lindau complex or polycythaemia: case report and literature review. , 1995, British journal of neurosurgery.

[124]  J. Hughes,et al.  Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease — a contiguous gene syndrome , 1994, Nature Genetics.

[125]  A. Knudson,et al.  Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[126]  A. Bardelli,et al.  Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. , 1994, Journal of biotechnology.

[127]  T. Shuin,et al.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. , 1994, Cancer research.

[128]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[129]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[130]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[131]  A. Bardelli,et al.  A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family , 1994, Cell.

[132]  A. Green,et al.  Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients , 1994, Nature Genetics.

[133]  S. Thomas,et al.  Identification and characterization of the tuberous sclerosis gene on chromosome 16 , 1993, Cell.

[134]  M. Benson,et al.  Bilateral renal cell carcinoma in the Birt-Hogg-Dubé syndrome. , 1993, Journal of the American Academy of Dermatology.

[135]  H. Neumann,et al.  Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. , 1993, The New England journal of medicine.

[136]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[137]  M. Lush,et al.  Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus. , 1993, Human molecular genetics.

[138]  H. Aburatani,et al.  Clinical and Genetic Studies of Renal Cell Carcinomas in a Family with a Constitutional Chromosome 3; 8 Translocation: Genetics of Familial Renal Carcinoma , 1993, Annals of Internal Medicine.

[139]  E Medico,et al.  Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[140]  N. Fausto.  Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 , 1991 .

[141]  M. Lerman,et al.  Mapping of the von Hippel-Lindau disease locus to a small region of chromosome 3p by genetic linkage analysis. , 1991, Genomics.

[142]  H. Brambs,et al.  Pancreatic lesions in the von Hippel-Lindau syndrome. , 1991, Gastroenterology.

[143]  L. Naldini,et al.  The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation , 1991, Molecular and cellular biology.

[144]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[145]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[146]  G. Kovacs,et al.  Tissue‐specific expression of a constitutional 3;6 translocation: Development of multiple bilateral renal‐cell carcinomas , 1989, International journal of cancer.

[147]  Hsia Ye,et al.  von Hippel-Lindau disease affecting 43 members of a single kindred. , 1989 .

[148]  J. Haines,et al.  Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma , 1988, Nature.

[149]  J. Goedert,et al.  Polymastia and renal adenocarcinoma. , 1981, Annals of internal medicine.

[150]  W. J. Dubé,et al.  Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. , 1977, Archives of dermatology.

[151]  K. Melmon,et al.  Lindau's disease: Review of the literature and study of a large kindred , 1964 .